샘플 요청 목록

 카트 문의
시장보고서
상품코드
2079692

증거 접근 및 네트워크 분야 AI 시장 : 규모, 점유율, 업계 분석 보고서 - 컴포넌트별, 기술별, 최종 사용자별, 데이터 소스별, 지역별 전망 및 예측(2026-2033년)

Global AI In Evidence Access And Networks Market Size, Share & Industry Analysis Report By Component, By Technology, By End User, By Data Source, By Regional Outlook and Forecast, 2026 - 2033
발행일: | 리서치사: 구분자 KBV Research | 페이지 정보: 영문 611 Pages | 배송안내 : 즉시배송

    
    
    



가격
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 3,600 금액 안내 화살표 ￦ 5,461,000
PDF (Multi User License) help
PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,320 금액 안내 화살표 ￦ 6,553,000
PDF (Corporate User License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,048 금액 안내 화살표 ￦ 9,174,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 증거 접근 및 네트워크 분야 AI 시장은 2033년까지 29억 6,150만 달러에 이를 것으로 예상되고 있어 2026-2033년까지 CAGR 37.3%로 성장할 전망입니다.

세계 증거 접근 및 네트워크 분야 AI 시장은 리얼 월드 에비던스(RWE), 의료 상호운용성, 그리고 AI를 활용한 분석에 대한 수요 증가에 힘입어, 헬스케어 및 생명과학 분야의 인텔리전스 분야에서 급속히 발전하고 있는 부문입니다. 이 시장은 기존의 의료 데이터 저장소 및 근거 관리 시스템에서 임상 데이터, 운영 데이터, 유전체 데이터, 그리고 실세계 의료 데이터를 수집·분석하여 이해관계자들 간에 공유할 수 있는 지능적이고 상호 연결된 플랫폼으로 진화하고 있습니다.

주요 시장 동향 및 인사이트

  • 2025년, 북미는 매출 점유율의 45.51%를 차지했습니다. 이는 첨단 의료 분석 인프라, AI의 적극적인 도입, 그리고 주요 의료 기술 제공업체들의 존재에 힘입은 결과입니다.
  • 상호 운용 가능한 의료 데이터 생태계에 대한 수요가 증가함에 따라, 2025년에는 ‘데이터 플랫폼 및 네트워크’가 시장 점유율 53.16%를 차지하며 주요 구성 요소 부문으로 부상했습니다.
  • 자연어 처리(NLP)는 임상 기록, 의학 문헌, 전자 건강 기록(EHR) 등 비정형 의료 데이터의 활용 확대에 힘입어 2025년에는 매출 점유율의 43.90%를 차지했습니다.
  • 제약·바이오기술 기업들은 증거 기반 의약품 개발 및 AI를 활용한 임상 연구에 대한 투자를 확대함에 따라, 2025년에는 매출 점유율 40.16%를 차지하며 최대의 최종 사용자 부문이 되었습니다.
  • 2025년에는 데이터 소스 중 전자건강기록(EHR)이 32.49%의 시장 점유율을 차지할 것으로 예상되며, 이는 근거 창출에 있어 디지털 의료 기록의 중요성이 높아지고 있음을 반영합니다.
  • AI를 활용한 실세계 증거(RWE) 플랫폼의 도입 확대에 따라, 임상적 인사이트를 신속하게 확보하고, 환자 세분화를 개선하며, 보다 효율적인 의료 조사 방법을 실현할 수 있게 되었습니다.
  • 분산형 및 연합형 에비던스 네트워크의 도입이 확대됨에 따라, 의료 생태계 전반에 걸쳐 데이터 접근성, 연계성 및 개인정보 보호를 보장하는 분석 능력이 향상되고 있습니다.

인공지능, 머신러닝, 자연어 처리, 예측 분석의 발전으로 인해 증거 생성 과정이 혁신을 이루었으며, 제약 기업, 의료 제공업체, 보험사, 연구 기관이 대규모 의료 데이터 세트에서 실행 가능한 인사이트를 도출할 수 있게 되었습니다. 증거 기반 의사결정, 정밀의학, 가치 기반 의료, 그리고 규제 기준을 충족하는 실세계 증거에 대한 관심이 높아지고 있는 것이 이러한 도입을 더욱 가속화하고 있습니다. 조직들은 임상 연구 개선, 환자 예후 최적화, 의료 업무 효율화 및 규제 당국에 대한 신청 지원을 위해 AI를 활용한 에비던스 네트워크에 대한 의존도를 높이고 있으며, 이 시장은 미래 헬스케어 인텔리전스 생태계의 핵심 구성 요소로서의 입지를 확립해 가고 있습니다.

의료 기관들이 파편화된 의료 데이터를 실행 가능한 인사이트으로 전환하기 위해 노력하는 가운데, 증거 접근 및 네트워크 분야 AI 시장은 눈부신 성장세를 보이고 있습니다. 의료 상호운용성, AI 기반 분석, 실세계 근거 생성 및 정밀의료 노력이 융합됨에 따라, 임상 혁신, 의료 최적화 및 규제 관련 의사결정을 지원할 수 있는 고도로 연계된 근거 생태계가 형성되고 있습니다. 클라우드 컴퓨팅, 의료 데이터 네트워크, 예측 분석 및 AI를 활용한 의료 인텔리전스에 대한 지속적인 투자를 통해, 예측 기간 동안 시장의 강력한 성장이 유지될 것으로 전망됩니다.

성장 촉진요인

  • 세계 정보 네트워크에 대한 접근성 향상 및 AI 통합 가속화
  • AI를 활용한 의료 분석 및 근거 생성에 대한 투자 증가
  • 정밀의료 및 실세계 근거 플랫폼의 도입 확대
  • 의료 인프라의 디지털 전환 및 상호운용성 확보를 위한 노력

제약 요인

  • 복잡한 규제 및 윤리적 준수 요건
  • 높은 도입 및 운영 비용
  • 데이터 상호운용성 및 네트워크 보안과 관련된 과제

기회

  • AI를 활용한 실세계 근거 생성 플랫폼의 확대
  • 안전하고 분산형인 증거 공유 네트워크의 개발
  • 예측 분석 및 정밀의료 인텔리전스의 응용

과제

  • 데이터 개인정보 보호 및 규정 준수와 관련된 제약 사항
  • 분산된 의료 인프라와 상호운용성의 제약
  • 막대한 기술 투자와 ROI의 불확실성

목차

제1장 조사 범위 및 조사 방법

제2장 시장 개요

제3장 시장에 영향을 미치는 주요 요인

제4장 제품수명주기

제5장 밸류체인 분석 : 증거 접근 및 네트워크 분야 AI 시장 :

제6장 경쟁 분석 : 세계

제7장 구성요소별 분류

제8장 기술별 세분화

제9장 최종 사용자별 세분화

제10장 데이터 소스별 분류

제11장 북미 시장

제12장 유럽 시장

제13장 아시아태평양 시장

제14장 라틴아메리카 및 중동 시장

제15장 기업 개요

제16장 성공을 위한 필수 요건 : 증거 접근 및 네트워크 분야 AI 시장

JHS

The Global AI in Evidence Access and Networks Market is expected to reach USD 2,961.50 million by 2033, growing at a CAGR of 37.3% during 2026 - 2033.

The Global AI in Evidence Access and Networks Market represents a rapidly evolving segment within healthcare and life sciences intelligence, driven by the increasing demand for real-world evidence (RWE), healthcare interoperability, and AI-powered analytics. The market has evolved from traditional healthcare data repositories and evidence management systems toward intelligent, interconnected platforms capable of aggregating, analyzing, and distributing clinical, operational, genomic, and real-world healthcare data across stakeholders.

Key Market Trends & Insights

  • North America accounted for 45.51% revenue share in 2025, supported by advanced healthcare analytics infrastructure, strong AI adoption, and the presence of leading healthcare technology providers.
  • Data Platforms and Networks emerged as the leading component segment with 53.16% market share in 2025 due to increasing demand for interoperable healthcare data ecosystems.
  • Natural Language Processing (NLP) captured 43.90% revenue share in 2025, driven by growing utilization of unstructured healthcare data including clinical notes, medical literature, and electronic health records.
  • Pharmaceutical and Biotech Companies represented the largest end-user segment with 40.16% revenue share in 2025 due to increasing investments in evidence-based drug development and AI-driven clinical research.
  • Electronic Health Records (EHR) accounted for 32.49% market share among data sources in 2025, reflecting the growing importance of digital healthcare records in evidence generation.
  • Growing adoption of AI-powered real-world evidence platforms is enabling faster clinical insights, improved patient stratification, and more efficient healthcare research processes.
  • Increasing deployment of decentralized and federated evidence networks is enhancing data accessibility, collaboration, and privacy-preserving analytics capabilities across healthcare ecosystems.

Advances in artificial intelligence, machine learning, natural language processing, and predictive analytics have transformed evidence generation processes, enabling pharmaceutical companies, healthcare providers, payers, and research organizations to derive actionable insights from large-scale healthcare datasets. The growing emphasis on evidence-based decision-making, precision medicine, value-based care, and regulatory-grade real-world evidence is further accelerating adoption. Organizations increasingly rely on AI-enabled evidence networks to improve clinical research, optimize patient outcomes, streamline healthcare operations, and support regulatory submissions, positioning the market as a critical component of the future healthcare intelligence ecosystem.

The AI in Evidence Access and Networks Market is experiencing significant momentum as healthcare organizations seek to transform fragmented healthcare data into actionable intelligence. The convergence of healthcare interoperability, AI-driven analytics, real-world evidence generation, and precision medicine initiatives is creating a highly connected evidence ecosystem capable of supporting clinical innovation, healthcare optimization, and regulatory decision-making. Continued investments in cloud computing, healthcare data networks, predictive analytics, and AI-powered healthcare intelligence are expected to sustain strong market growth throughout the forecast period.

Drivers

  • Enhanced Access to Global Information Networks Accelerating AI Integration
  • Rising Investment in AI-Driven Healthcare Analytics and Evidence Generation
  • Growing Adoption of Precision Medicine and Real-World Evidence Platforms
  • Digital Transformation of Healthcare Infrastructure and Interoperability Initiatives

Restraints

  • Complex Regulatory and Ethical Compliance Requirements
  • High Implementation and Operational Costs
  • Data Interoperability and Network Security Challenges

Opportunities

  • Expansion of AI-Driven Real-World Evidence Generation Platforms
  • Development of Secure and Federated Evidence Sharing Networks
  • Predictive Analytics and Precision Healthcare Intelligence Applications

Challenges

  • Data Privacy and Regulatory Compliance Constraints
  • Fragmented Healthcare Infrastructure and Interoperability Limitations
  • High Technology Investment and ROI Uncertainty

Market Share Analysis

IQVIA leads the AI in Evidence Access and Networks Market supported by its extensive healthcare datasets, AI-enabled analytics platforms, and strong life sciences partnerships. Optum follows, leveraging large-scale healthcare claims databases and payer-provider integration capabilities.

Flatiron Health accounts for 10.27% share, driven by its oncology-focused evidence generation platforms and advanced clinical intelligence capabilities. Other major participants include TriNetX, Komodo Health, Oracle, SAS Institute, Aetion, ICON plc, and Syneos Health. Competition is centered on healthcare data scale, AI analytics sophistication, interoperability infrastructure, regulatory-grade evidence generation, and healthcare network connectivity.

Component Outlook

Based on Component, the market is segmented into Data Platforms and Networks and Analytics and Technologies.

Data Platforms and Networks dominated the market in 2025 with a 53.16% revenue share, driven by increasing demand for integrated healthcare data ecosystems capable of aggregating, managing, and exchanging clinical, operational, and real-world evidence data. Healthcare organizations, pharmaceutical companies, and research institutions increasingly deploy advanced healthcare data networks to improve interoperability, support evidence generation, and accelerate healthcare decision-making.

Analytics and Technologies growth is supported by growing adoption of AI-powered analytics platforms that enable predictive insights, patient stratification, healthcare forecasting, and evidence-based clinical decision-making.

Technology Outlook

Based on Technology, the market is segmented into Natural Language Processing (NLP), Machine Learning (ML) and Predictive Analytics, and Other Technologies.

The Data Platforms and Networks market dominated the Global AI In Evidence Access And Networks Market by Component in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1517 million by 2033, growing at a CAGR of 16.5% during the forecast period.

Natural Language Processing dominated the market with a 43.90% revenue share in 2025 owing to growing utilization of unstructured healthcare data such as physician notes, medical literature, and clinical documentation. Machine Learning and Predictive Analytics represented 38.44% share, driven by increasing demand for predictive healthcare modeling, patient risk assessment, and evidence-based treatment optimization.

End User Outlook

Based on End User, the market is segmented into Pharmaceutical and Biotech Companies, Healthcare Providers and Payers, Contract Research Organizations (CROs), and Other End Users.

Pharmaceutical and Biotech Companies led the market with 40.16% revenue share in 2025, reflecting increasing investments in AI-enabled evidence generation, clinical trial optimization, drug development, and regulatory intelligence. Healthcare Providers and Payers accounted for 26.89% share, supported by adoption of evidence-based care delivery and population health management initiatives. CROs represented 24.61% share, driven by increasing use of AI-enabled research platforms and outsourced clinical research services. Other End Users, including academic institutions and public health organizations, accounted for 8.35% share.

Data Source Outlook

Based on Data Source, the market is segmented into Electronic Health Records (EHR), Claims and Billing Data, Genomic and Omics Data, Patient Registries, and Other Data Sources.

The Electronic Health Records (EHR) market dominated the Global AI In Evidence Access And Networks Market by Data Source in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 904.9 million by 2033, growing at a CAGR of 16.1 % during the forecast period.

Electronic Health Records emerged as the leading data source segment with 32.49% revenue share in 2025 due to increasing adoption of digital healthcare systems and availability of structured clinical information. Claims and Billing Data accounted for 26.94% share, supporting healthcare utilization analysis and cost management initiatives. Genomic and Omics Data represented 16.05% share, driven by precision medicine and personalized healthcare programs. Patient Registries captured 14.84% share, while Other Data Sources including wearable devices, imaging systems, and social determinants of health accounted for 9.69% share.

Regional Outlook

Region-wise, the AI in Evidence Access and Networks Market is analyzed across North America, Europe, Asia Pacific, and LAMEA.

The North America market dominated the Global AI In Evidence Access And Networks Market by Region in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1305.1 million by 2033, growing at a CAGR of 16.5 % during the forecast period. The Europe market is expected to witness a CAGR of 16.8% during (2026 - 2033).

Europe accounted for 28.17% share, supported by increasing healthcare digitalization and interoperability initiatives. Asia Pacific captured 20.58% share, driven by expanding healthcare infrastructure, AI adoption, and healthcare research investments.

Global AI In Evidence Access And Networks Market

Recent Strategies Deployed in the Market

  • Optum launched its AI-powered Value Connect Platform to support value-based healthcare through integrated evidence access and analytics capabilities.
  • Flatiron Health expanded AI-enabled real-world evidence capabilities focused on oncology research and predictive healthcare intelligence.
  • SAS introduced advanced healthcare AI and evidence modeling capabilities through SAS Innovate 2026.
  • Oracle expanded healthcare cloud infrastructure and AI-enabled data integration solutions supporting evidence-based healthcare ecosystems.
  • Flatiron Health partnered with University Hospitals of Leicester NHS Trust to strengthen oncology evidence generation and clinical research collaboration.
  • Komodo Health collaborated with pharmaceutical organizations to accelerate AI-powered real-world evidence generation and healthcare analytics initiatives.
  • IQVIA expanded AI-driven operational intelligence solutions to improve clinical trial execution and evidence accessibility across global research networks.
  • Flatiron Health expanded cross-border patient-level data sharing capabilities to support international healthcare research and precision medicine initiatives.

List of Key Companies Profiled

  • IQVIA
  • Optum
  • Flatiron Health
  • TriNetX
  • Komodo Health
  • Oracle Corporation
  • SAS Institute Inc.
  • Aetion, Inc.
  • ICON plc
  • Syneos Health

Global AI in Evidence Access and Networks Market Segmentation

By Component

  • Data Platforms and Networks
  • Analytics and Technologies

By Technology

  • Natural Language Processing (NLP)
  • Machine Learning (ML) and Predictive Analytics
  • Other Technologies

By End User

  • Pharmaceutical and Biotech Companies
  • Healthcare Providers and Payers
  • Contract Research Organizations (CROs)
  • Other End Users

By Data Source

  • Electronic Health Records (EHR)
  • Claims and Billing Data
  • Genomic and Omics Data
  • Patient Registries
  • Other Data Sources

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Table of Contents

Chapter 1. Research Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Analysis Period & Currency
  • 1.3 Segmentation
    • 1.3.1 AI In Evidence Access And Networks Market, by Component
    • 1.3.2 AI In Evidence Access And Networks Market, by Technology
    • 1.3.3 AI In Evidence Access And Networks Market, by End User
    • 1.3.4 AI In Evidence Access And Networks Market, by Data Source
    • 1.3.5 AI In Evidence Access And Networks Market, by Geography
  • 1.4 Research Methodology

Chapter 2. Market Overview

  • 2.1 COVID-19 Impact
  • 2.2 Market Composition and Scenario

Chapter 3. Key Factors Impacting Market

  • 3.1 Market Drivers
  • 3.2 Market Restraints
  • 3.3 Market Opportunities
  • 3.4 Market Challenges
  • 3.5 Market Trends
  • 3.6 State of Competition
  • 3.7 Market Consolidation
  • 3.8 Key Customer Criteria

Chapter 4. Product Life Cycle

Chapter 5. Value Chain Analysis of AI In Evidence Access And Networks Market

Chapter 6. Competition Analysis - Global

  • 6.1 Market Share Analysis
  • 6.2 Recent Developments and Strategies
    • 6.2.1 Mergers & Acquisitions
    • 6.2.2 Product Launch & Product Expansion
    • 6.2.3 Partnership, Collaboration & Agreements
    • 6.2.4 Geographical Expansion

Chapter 7. Segmentation By Component

  • 7.1 Data Platforms and Networks
  • 7.2 Analytics and Technology

Chapter 8. Segmentation By Technology

  • 8.1 Natural Language Processing (NLP)
  • 8.2 Machine Learning (ML) and Predictive Analytics
  • 8.3 Other Technology

Chapter 9. Segmentation By End User

  • 9.1 Pharmaceutical and Biotech Companies
  • 9.2 Healthcare Providers and Payers
  • 9.3 Contract Research Organizations (CROs)
  • 9.4 Other End User

Chapter 10. Segmentation By Data Source

  • 10.1 Electronic Health Records (EHR)
  • 10.2 Claims and Billing Data
  • 10.3 Genomic and Omics Data
  • 10.4 Patient Registries
  • 10.5 Other Data Source

Chapter 11. North America Market

  • 11.1 Market Overview
  • 11.2 Key Factors Impacting Market
    • 11.2.1 Market Drivers
    • 11.2.2 Market Restraints
    • 11.2.3 Market Opportunities
    • 11.2.4 Market Challenges
    • 11.2.5 Market Trends
    • 11.2.6 State of Competition
    • 11.2.7 Market Consolidation
    • 11.2.8 Key Customer Criteria
  • 11.3 Product Life Cycle
  • 11.4 Segmentation By Component
    • 11.4.1 Data Platforms and Networks
    • 11.4.2 Analytics and Technology
  • 11.5 Segmentation By Technology
    • 11.5.1 Natural Language Processing (NLP)
    • 11.5.2 Machine Learning (ML) and Predictive Analytics
    • 11.5.3 Other Technology
  • 11.6 Segmentation By End User
    • 11.6.1 Pharmaceutical and Biotech Companies
    • 11.6.2 Healthcare Providers and Payers
    • 11.6.3 Contract Research Organizations (CROs)
    • 11.6.4 Other End User
  • 11.7 Segmentation By Data Source
    • 11.7.1 Electronic Health Records (EHR)
    • 11.7.2 Claims and Billing Data
    • 11.7.3 Genomic and Omics Data
    • 11.7.4 Patient Registries
    • 11.7.5 Other Data Source
  • 11.8 Segmentation By Country
    • 11.8.1 US
      • 11.8.1.1 Segmentation By Component
        • 11.8.1.1.1 Data Platforms and Networks
        • 11.8.1.1.2 Analytics and Technology
      • 11.8.1.2 Segmentation By Technology
        • 11.8.1.2.1 Natural Language Processing (NLP)
        • 11.8.1.2.2 Machine Learning (ML) and Predictive Analytics
        • 11.8.1.2.3 Other Technology
      • 11.8.1.3 Segmentation By End User
        • 11.8.1.3.1 Pharmaceutical and Biotech Companies
        • 11.8.1.3.2 Healthcare Providers and Payers
        • 11.8.1.3.3 Contract Research Organizations (CROs)
        • 11.8.1.3.4 Other End User
      • 11.8.1.4 Segmentation By Data Source
        • 11.8.1.4.1 Electronic Health Records (EHR)
        • 11.8.1.4.2 Claims and Billing Data
        • 11.8.1.4.3 Genomic and Omics Data
        • 11.8.1.4.4 Patient Registries
        • 11.8.1.4.5 Other Data Source
    • 11.8.2 Canada
      • 11.8.2.1 Segmentation By Component
        • 11.8.2.1.1 Data Platforms and Networks
        • 11.8.2.1.2 Analytics and Technology
      • 11.8.2.2 Segmentation By Technology
        • 11.8.2.2.1 Natural Language Processing (NLP)
        • 11.8.2.2.2 Machine Learning (ML) and Predictive Analytics
        • 11.8.2.2.3 Other Technology
      • 11.8.2.3 Segmentation By End User
        • 11.8.2.3.1 Pharmaceutical and Biotech Companies
        • 11.8.2.3.2 Healthcare Providers and Payers
        • 11.8.2.3.3 Contract Research Organizations (CROs)
        • 11.8.2.3.4 Other End User
      • 11.8.2.4 Segmentation By Data Source
        • 11.8.2.4.1 Electronic Health Records (EHR)
        • 11.8.2.4.2 Claims and Billing Data
        • 11.8.2.4.3 Genomic and Omics Data
        • 11.8.2.4.4 Patient Registries
        • 11.8.2.4.5 Other Data Source
    • 11.8.3 Mexico
      • 11.8.3.1 Segmentation By Component
        • 11.8.3.1.1 Data Platforms and Networks
        • 11.8.3.1.2 Analytics and Technology
      • 11.8.3.2 Segmentation By Technology
        • 11.8.3.2.1 Natural Language Processing (NLP)
        • 11.8.3.2.2 Machine Learning (ML) and Predictive Analytics
        • 11.8.3.2.3 Other Technology
      • 11.8.3.3 Segmentation By End User
        • 11.8.3.3.1 Pharmaceutical and Biotech Companies
        • 11.8.3.3.2 Healthcare Providers and Payers
        • 11.8.3.3.3 Contract Research Organizations (CROs)
        • 11.8.3.3.4 Other End User
      • 11.8.3.4 Segmentation By Data Source
        • 11.8.3.4.1 Electronic Health Records (EHR)
        • 11.8.3.4.2 Claims and Billing Data
        • 11.8.3.4.3 Genomic and Omics Data
        • 11.8.3.4.4 Patient Registries
        • 11.8.3.4.5 Other Data Source
    • 11.8.4 Rest of North America
      • 11.8.4.1 Segmentation By Component
        • 11.8.4.1.1 Data Platforms and Networks
        • 11.8.4.1.2 Analytics and Technology
      • 11.8.4.2 Segmentation By Technology
        • 11.8.4.2.1 Natural Language Processing (NLP)
        • 11.8.4.2.2 Machine Learning (ML) and Predictive Analytics
        • 11.8.4.2.3 Other Technology
      • 11.8.4.3 Segmentation By End User
        • 11.8.4.3.1 Pharmaceutical and Biotech Companies
        • 11.8.4.3.2 Healthcare Providers and Payers
        • 11.8.4.3.3 Contract Research Organizations (CROs)
        • 11.8.4.3.4 Other End User
      • 11.8.4.4 Segmentation By Data Source
        • 11.8.4.4.1 Electronic Health Records (EHR)
        • 11.8.4.4.2 Claims and Billing Data
        • 11.8.4.4.3 Genomic and Omics Data
        • 11.8.4.4.4 Patient Registries
        • 11.8.4.4.5 Other Data Source

Chapter 12. Europe Market

  • 12.1 Market Overview
  • 12.2 Key Factors Impacting Market
    • 12.2.1 Market Drivers
    • 12.2.2 Market Restraints
    • 12.2.3 Market Opportunities
    • 12.2.4 Market Challenges
    • 12.2.5 Market Trends
    • 12.2.6 State of Competition
    • 12.2.7 Market Consolidation
    • 12.2.8 Key Customer Criteria
  • 12.3 Product Life Cycle
  • 12.4 Segmentation By Component
    • 12.4.1 Data Platforms and Networks
    • 12.4.2 Analytics and Technology
  • 12.5 Segmentation By Technology
    • 12.5.1 Natural Language Processing (NLP)
    • 12.5.2 Machine Learning (ML) and Predictive Analytics
    • 12.5.3 Other Technology
  • 12.6 Segmentation By End User
    • 12.6.1 Pharmaceutical and Biotech Companies
    • 12.6.2 Healthcare Providers and Payers
    • 12.6.3 Contract Research Organizations (CROs)
    • 12.6.4 Other End User
  • 12.7 Segmentation By Data Source
    • 12.7.1 Electronic Health Records (EHR)
    • 12.7.2 Claims and Billing Data
    • 12.7.3 Genomic and Omics Data
    • 12.7.4 Patient Registries
    • 12.7.5 Other Data Source
  • 12.8 Segmentation By Country
    • 12.8.1 Germany
      • 12.8.1.1 Segmentation By Component
        • 12.8.1.1.1 Data Platforms and Networks
        • 12.8.1.1.2 Analytics and Technology
      • 12.8.1.2 Segmentation By Technology
        • 12.8.1.2.1 Natural Language Processing (NLP)
        • 12.8.1.2.2 Machine Learning (ML) and Predictive Analytics
        • 12.8.1.2.3 Other Technology
      • 12.8.1.3 Segmentation By End User
        • 12.8.1.3.1 Pharmaceutical and Biotech Companies
        • 12.8.1.3.2 Healthcare Providers and Payers
        • 12.8.1.3.3 Contract Research Organizations (CROs)
        • 12.8.1.3.4 Other End User
      • 12.8.1.4 Segmentation By Data Source
        • 12.8.1.4.1 Electronic Health Records (EHR)
        • 12.8.1.4.2 Claims and Billing Data
        • 12.8.1.4.3 Genomic and Omics Data
        • 12.8.1.4.4 Patient Registries
        • 12.8.1.4.5 Other Data Source
    • 12.8.2 UK
      • 12.8.2.1 Segmentation By Component
        • 12.8.2.1.1 Data Platforms and Networks
        • 12.8.2.1.2 Analytics and Technology
      • 12.8.2.2 Segmentation By Technology
        • 12.8.2.2.1 Natural Language Processing (NLP)
        • 12.8.2.2.2 Machine Learning (ML) and Predictive Analytics
        • 12.8.2.2.3 Other Technology
      • 12.8.2.3 Segmentation By End User
        • 12.8.2.3.1 Pharmaceutical and Biotech Companies
        • 12.8.2.3.2 Healthcare Providers and Payers
        • 12.8.2.3.3 Contract Research Organizations (CROs)
        • 12.8.2.3.4 Other End User
      • 12.8.2.4 Segmentation By Data Source
        • 12.8.2.4.1 Electronic Health Records (EHR)
        • 12.8.2.4.2 Claims and Billing Data
        • 12.8.2.4.3 Genomic and Omics Data
        • 12.8.2.4.4 Patient Registries
        • 12.8.2.4.5 Other Data Source
    • 12.8.3 France
      • 12.8.3.1 Segmentation By Component
        • 12.8.3.1.1 Data Platforms and Networks
        • 12.8.3.1.2 Analytics and Technology
      • 12.8.3.2 Segmentation By Technology
        • 12.8.3.2.1 Natural Language Processing (NLP)
        • 12.8.3.2.2 Machine Learning (ML) and Predictive Analytics
        • 12.8.3.2.3 Other Technology
      • 12.8.3.3 Segmentation By End User
        • 12.8.3.3.1 Pharmaceutical and Biotech Companies
        • 12.8.3.3.2 Healthcare Providers and Payers
        • 12.8.3.3.3 Contract Research Organizations (CROs)
        • 12.8.3.3.4 Other End User
      • 12.8.3.4 Segmentation By Data Source
        • 12.8.3.4.1 Electronic Health Records (EHR)
        • 12.8.3.4.2 Claims and Billing Data
        • 12.8.3.4.3 Genomic and Omics Data
        • 12.8.3.4.4 Patient Registries
        • 12.8.3.4.5 Other Data Source
    • 12.8.4 Russia
      • 12.8.4.1 Segmentation By Component
        • 12.8.4.1.1 Data Platforms and Networks
        • 12.8.4.1.2 Analytics and Technology
      • 12.8.4.2 Segmentation By Technology
        • 12.8.4.2.1 Natural Language Processing (NLP)
        • 12.8.4.2.2 Machine Learning (ML) and Predictive Analytics
        • 12.8.4.2.3 Other Technology
      • 12.8.4.3 Segmentation By End User
        • 12.8.4.3.1 Pharmaceutical and Biotech Companies
        • 12.8.4.3.2 Healthcare Providers and Payers
        • 12.8.4.3.3 Contract Research Organizations (CROs)
        • 12.8.4.3.4 Other End User
      • 12.8.4.4 Segmentation By Data Source
        • 12.8.4.4.1 Electronic Health Records (EHR)
        • 12.8.4.4.2 Claims and Billing Data
        • 12.8.4.4.3 Genomic and Omics Data
        • 12.8.4.4.4 Patient Registries
        • 12.8.4.4.5 Other Data Source
    • 12.8.5 Spain
      • 12.8.5.1 Segmentation By Component
        • 12.8.5.1.1 Data Platforms and Networks
        • 12.8.5.1.2 Analytics and Technology
      • 12.8.5.2 Segmentation By Technology
        • 12.8.5.2.1 Natural Language Processing (NLP)
        • 12.8.5.2.2 Machine Learning (ML) and Predictive Analytics
        • 12.8.5.2.3 Other Technology
      • 12.8.5.3 Segmentation By End User
        • 12.8.5.3.1 Pharmaceutical and Biotech Companies
        • 12.8.5.3.2 Healthcare Providers and Payers
        • 12.8.5.3.3 Contract Research Organizations (CROs)
        • 12.8.5.3.4 Other End User
      • 12.8.5.4 Segmentation By Data Source
        • 12.8.5.4.1 Electronic Health Records (EHR)
        • 12.8.5.4.2 Claims and Billing Data
        • 12.8.5.4.3 Genomic and Omics Data
        • 12.8.5.4.4 Patient Registries
        • 12.8.5.4.5 Other Data Source
    • 12.8.6 Italy
      • 12.8.6.1 Segmentation By Component
        • 12.8.6.1.1 Data Platforms and Networks
        • 12.8.6.1.2 Analytics and Technology
      • 12.8.6.2 Segmentation By Technology
        • 12.8.6.2.1 Natural Language Processing (NLP)
        • 12.8.6.2.2 Machine Learning (ML) and Predictive Analytics
        • 12.8.6.2.3 Other Technology
      • 12.8.6.3 Segmentation By End User
        • 12.8.6.3.1 Pharmaceutical and Biotech Companies
        • 12.8.6.3.2 Healthcare Providers and Payers
        • 12.8.6.3.3 Contract Research Organizations (CROs)
        • 12.8.6.3.4 Other End User
      • 12.8.6.4 Segmentation By Data Source
        • 12.8.6.4.1 Electronic Health Records (EHR)
        • 12.8.6.4.2 Claims and Billing Data
        • 12.8.6.4.3 Genomic and Omics Data
        • 12.8.6.4.4 Patient Registries
        • 12.8.6.4.5 Other Data Source
    • 12.8.7 Rest of Europe
      • 12.8.7.1 Segmentation By Component
        • 12.8.7.1.1 Data Platforms and Networks
        • 12.8.7.1.2 Analytics and Technology
      • 12.8.7.2 Segmentation By Technology
        • 12.8.7.2.1 Natural Language Processing (NLP)
        • 12.8.7.2.2 Machine Learning (ML) and Predictive Analytics
        • 12.8.7.2.3 Other Technology
      • 12.8.7.3 Segmentation By End User
        • 12.8.7.3.1 Pharmaceutical and Biotech Companies
        • 12.8.7.3.2 Healthcare Providers and Payers
        • 12.8.7.3.3 Contract Research Organizations (CROs)
        • 12.8.7.3.4 Other End User
      • 12.8.7.4 Segmentation By Data Source
        • 12.8.7.4.1 Electronic Health Records (EHR)
        • 12.8.7.4.2 Claims and Billing Data
        • 12.8.7.4.3 Genomic and Omics Data
        • 12.8.7.4.4 Patient Registries
        • 12.8.7.4.5 Other Data Source

Chapter 13. Asia Pacific Market

  • 13.1 Market Overview
  • 13.2 Key Factors Impacting Market
    • 13.2.1 Market Drivers
    • 13.2.2 Market Restraints
    • 13.2.3 Market Opportunities
    • 13.2.4 Market Challenges
    • 13.2.5 Market Trends
    • 13.2.6 State of Competition
    • 13.2.7 Market Consolidation
    • 13.2.8 Key Customer Criteria
  • 13.3 Product Life Cycle
  • 13.4 Segmentation By Component
    • 13.4.1 Data Platforms and Networks
    • 13.4.2 Analytics and Technology
  • 13.5 Segmentation By Technology
    • 13.5.1 Natural Language Processing (NLP)
    • 13.5.2 Machine Learning (ML) and Predictive Analytics
    • 13.5.3 Other Technology
  • 13.6 Segmentation By End User
    • 13.6.1 Pharmaceutical and Biotech Companies
    • 13.6.2 Healthcare Providers and Payers
    • 13.6.3 Contract Research Organizations (CROs)
    • 13.6.4 Other End User
  • 13.7 Segmentation By Data Source
    • 13.7.1 Electronic Health Records (EHR)
    • 13.7.2 Claims and Billing Data
    • 13.7.3 Genomic and Omics Data
    • 13.7.4 Patient Registries
    • 13.7.5 Other Data Source
  • 13.8 Segmentation By Country
    • 13.8.1 China
      • 13.8.1.1 Segmentation By Component
        • 13.8.1.1.1 Data Platforms and Networks
        • 13.8.1.1.2 Analytics and Technology
      • 13.8.1.2 Segmentation By Technology
        • 13.8.1.2.1 Natural Language Processing (NLP)
        • 13.8.1.2.2 Machine Learning (ML) and Predictive Analytics
        • 13.8.1.2.3 Other Technology
      • 13.8.1.3 Segmentation By End User
        • 13.8.1.3.1 Pharmaceutical and Biotech Companies
        • 13.8.1.3.2 Healthcare Providers and Payers
        • 13.8.1.3.3 Contract Research Organizations (CROs)
        • 13.8.1.3.4 Other End User
      • 13.8.1.4 Segmentation By Data Source
        • 13.8.1.4.1 Electronic Health Records (EHR)
        • 13.8.1.4.2 Claims and Billing Data
        • 13.8.1.4.3 Genomic and Omics Data
        • 13.8.1.4.4 Patient Registries
        • 13.8.1.4.5 Other Data Source
    • 13.8.2 Japan
      • 13.8.2.1 Segmentation By Component
        • 13.8.2.1.1 Data Platforms and Networks
        • 13.8.2.1.2 Analytics and Technology
      • 13.8.2.2 Segmentation By Technology
        • 13.8.2.2.1 Natural Language Processing (NLP)
        • 13.8.2.2.2 Machine Learning (ML) and Predictive Analytics
        • 13.8.2.2.3 Other Technology
      • 13.8.2.3 Segmentation By End User
        • 13.8.2.3.1 Pharmaceutical and Biotech Companies
        • 13.8.2.3.2 Healthcare Providers and Payers
        • 13.8.2.3.3 Contract Research Organizations (CROs)
        • 13.8.2.3.4 Other End User
      • 13.8.2.4 Segmentation By Data Source
        • 13.8.2.4.1 Electronic Health Records (EHR)
        • 13.8.2.4.2 Claims and Billing Data
        • 13.8.2.4.3 Genomic and Omics Data
        • 13.8.2.4.4 Patient Registries
        • 13.8.2.4.5 Other Data Source
    • 13.8.3 India
      • 13.8.3.1 Segmentation By Component
        • 13.8.3.1.1 Data Platforms and Networks
        • 13.8.3.1.2 Analytics and Technology
      • 13.8.3.2 Segmentation By Technology
        • 13.8.3.2.1 Natural Language Processing (NLP)
        • 13.8.3.2.2 Machine Learning (ML) and Predictive Analytics
        • 13.8.3.2.3 Other Technology
      • 13.8.3.3 Segmentation By End User
        • 13.8.3.3.1 Pharmaceutical and Biotech Companies
        • 13.8.3.3.2 Healthcare Providers and Payers
        • 13.8.3.3.3 Contract Research Organizations (CROs)
        • 13.8.3.3.4 Other End User
      • 13.8.3.4 Segmentation By Data Source
        • 13.8.3.4.1 Electronic Health Records (EHR)
        • 13.8.3.4.2 Claims and Billing Data
        • 13.8.3.4.3 Genomic and Omics Data
        • 13.8.3.4.4 Patient Registries
        • 13.8.3.4.5 Other Data Source
    • 13.8.4 South Korea
      • 13.8.4.1 Segmentation By Component
        • 13.8.4.1.1 Data Platforms and Networks
        • 13.8.4.1.2 Analytics and Technology
      • 13.8.4.2 Segmentation By Technology
        • 13.8.4.2.1 Natural Language Processing (NLP)
        • 13.8.4.2.2 Machine Learning (ML) and Predictive Analytics
        • 13.8.4.2.3 Other Technology
      • 13.8.4.3 Segmentation By End User
        • 13.8.4.3.1 Pharmaceutical and Biotech Companies
        • 13.8.4.3.2 Healthcare Providers and Payers
        • 13.8.4.3.3 Contract Research Organizations (CROs)
        • 13.8.4.3.4 Other End User
      • 13.8.4.4 Segmentation By Data Source
        • 13.8.4.4.1 Electronic Health Records (EHR)
        • 13.8.4.4.2 Claims and Billing Data
        • 13.8.4.4.3 Genomic and Omics Data
        • 13.8.4.4.4 Patient Registries
        • 13.8.4.4.5 Other Data Source
    • 13.8.5 Singapore
      • 13.8.5.1 Segmentation By Component
        • 13.8.5.1.1 Data Platforms and Networks
        • 13.8.5.1.2 Analytics and Technology
      • 13.8.5.2 Segmentation By Technology
        • 13.8.5.2.1 Natural Language Processing (NLP)
        • 13.8.5.2.2 Machine Learning (ML) and Predictive Analytics
        • 13.8.5.2.3 Other Technology
      • 13.8.5.3 Segmentation By End User
        • 13.8.5.3.1 Pharmaceutical and Biotech Companies
        • 13.8.5.3.2 Healthcare Providers and Payers
        • 13.8.5.3.3 Contract Research Organizations (CROs)
        • 13.8.5.3.4 Other End User
      • 13.8.5.4 Segmentation By Data Source
        • 13.8.5.4.1 Electronic Health Records (EHR)
        • 13.8.5.4.2 Claims and Billing Data
        • 13.8.5.4.3 Genomic and Omics Data
        • 13.8.5.4.4 Patient Registries
        • 13.8.5.4.5 Other Data Source
    • 13.8.6 Malaysia
      • 13.8.6.1 Segmentation By Component
        • 13.8.6.1.1 Data Platforms and Networks
        • 13.8.6.1.2 Analytics and Technology
      • 13.8.6.2 Segmentation By Technology
        • 13.8.6.2.1 Natural Language Processing (NLP)
        • 13.8.6.2.2 Machine Learning (ML) and Predictive Analytics
        • 13.8.6.2.3 Other Technology
      • 13.8.6.3 Segmentation By End User
        • 13.8.6.3.1 Pharmaceutical and Biotech Companies
        • 13.8.6.3.2 Healthcare Providers and Payers
        • 13.8.6.3.3 Contract Research Organizations (CROs)
        • 13.8.6.3.4 Other End User
      • 13.8.6.4 Segmentation By Data Source
        • 13.8.6.4.1 Electronic Health Records (EHR)
        • 13.8.6.4.2 Claims and Billing Data
        • 13.8.6.4.3 Genomic and Omics Data
        • 13.8.6.4.4 Patient Registries
        • 13.8.6.4.5 Other Data Source
    • 13.8.7 Rest of Asia Pacific
      • 13.8.7.1 Segmentation By Component
        • 13.8.7.1.1 Data Platforms and Networks
        • 13.8.7.1.2 Analytics and Technology
      • 13.8.7.2 Segmentation By Technology
        • 13.8.7.2.1 Natural Language Processing (NLP)
        • 13.8.7.2.2 Machine Learning (ML) and Predictive Analytics
        • 13.8.7.2.3 Other Technology
      • 13.8.7.3 Segmentation By End User
        • 13.8.7.3.1 Pharmaceutical and Biotech Companies
        • 13.8.7.3.2 Healthcare Providers and Payers
        • 13.8.7.3.3 Contract Research Organizations (CROs)
        • 13.8.7.3.4 Other End User
      • 13.8.7.4 Segmentation By Data Source
        • 13.8.7.4.1 Electronic Health Records (EHR)
        • 13.8.7.4.2 Claims and Billing Data
        • 13.8.7.4.3 Genomic and Omics Data
        • 13.8.7.4.4 Patient Registries
        • 13.8.7.4.5 Other Data Source

Chapter 14. LAMEA Market

  • 14.1 Market Overview
  • 14.2 Key Factors Impacting Market
    • 14.2.1 Market Drivers
    • 14.2.2 Market Restraints
    • 14.2.3 Market Opportunities
    • 14.2.4 Market Challenges
    • 14.2.5 Market Trends
    • 14.2.6 State of Competition
    • 14.2.7 Market Consolidation
    • 14.2.8 Key Customer Criteria
  • 14.3 Product Life Cycle
  • 14.4 Segmentation By Component
    • 14.4.1 Data Platforms and Networks
    • 14.4.2 Analytics and Technology
  • 14.5 Segmentation By Technology
    • 14.5.1 Natural Language Processing (NLP)
    • 14.5.2 Machine Learning (ML) and Predictive Analytics
    • 14.5.3 Other Technology
  • 14.6 Segmentation By End User
    • 14.6.1 Pharmaceutical and Biotech Companies
    • 14.6.2 Healthcare Providers and Payers
    • 14.6.3 Contract Research Organizations (CROs)
    • 14.6.4 Other End User
  • 14.7 Segmentation By Data Source
    • 14.7.1 Electronic Health Records (EHR)
    • 14.7.2 Claims and Billing Data
    • 14.7.3 Genomic and Omics Data
    • 14.7.4 Patient Registries
    • 14.7.5 Other Data Source
  • 14.8 Segmentation By Country
    • 14.8.1 Brazil
      • 14.8.1.1 Segmentation By Component
        • 14.8.1.1.1 Data Platforms and Networks
        • 14.8.1.1.2 Analytics and Technology
      • 14.8.1.2 Segmentation By Technology
        • 14.8.1.2.1 Natural Language Processing (NLP)
        • 14.8.1.2.2 Machine Learning (ML) and Predictive Analytics
        • 14.8.1.2.3 Other Technology
      • 14.8.1.3 Segmentation By End User
        • 14.8.1.3.1 Pharmaceutical and Biotech Companies
        • 14.8.1.3.2 Healthcare Providers and Payers
        • 14.8.1.3.3 Contract Research Organizations (CROs)
        • 14.8.1.3.4 Other End User
      • 14.8.1.4 Segmentation By Data Source
        • 14.8.1.4.1 Electronic Health Records (EHR)
        • 14.8.1.4.2 Claims and Billing Data
        • 14.8.1.4.3 Genomic and Omics Data
        • 14.8.1.4.4 Patient Registries
        • 14.8.1.4.5 Other Data Source
    • 14.8.2 Argentina
      • 14.8.2.1 Segmentation By Component
        • 14.8.2.1.1 Data Platforms and Networks
        • 14.8.2.1.2 Analytics and Technology
      • 14.8.2.2 Segmentation By Technology
        • 14.8.2.2.1 Natural Language Processing (NLP)
        • 14.8.2.2.2 Machine Learning (ML) and Predictive Analytics
        • 14.8.2.2.3 Other Technology
      • 14.8.2.3 Segmentation By End User
        • 14.8.2.3.1 Pharmaceutical and Biotech Companies
        • 14.8.2.3.2 Healthcare Providers and Payers
        • 14.8.2.3.3 Contract Research Organizations (CROs)
        • 14.8.2.3.4 Other End User
      • 14.8.2.4 Segmentation By Data Source
        • 14.8.2.4.1 Electronic Health Records (EHR)
        • 14.8.2.4.2 Claims and Billing Data
        • 14.8.2.4.3 Genomic and Omics Data
        • 14.8.2.4.4 Patient Registries
        • 14.8.2.4.5 Other Data Source
    • 14.8.3 UAE
      • 14.8.3.1 Segmentation By Component
        • 14.8.3.1.1 Data Platforms and Networks
        • 14.8.3.1.2 Analytics and Technology
      • 14.8.3.2 Segmentation By Technology
        • 14.8.3.2.1 Natural Language Processing (NLP)
        • 14.8.3.2.2 Machine Learning (ML) and Predictive Analytics
        • 14.8.3.2.3 Other Technology
      • 14.8.3.3 Segmentation By End User
        • 14.8.3.3.1 Pharmaceutical and Biotech Companies
        • 14.8.3.3.2 Healthcare Providers and Payers
        • 14.8.3.3.3 Contract Research Organizations (CROs)
        • 14.8.3.3.4 Other End User
      • 14.8.3.4 Segmentation By Data Source
        • 14.8.3.4.1 Electronic Health Records (EHR)
        • 14.8.3.4.2 Claims and Billing Data
        • 14.8.3.4.3 Genomic and Omics Data
        • 14.8.3.4.4 Patient Registries
        • 14.8.3.4.5 Other Data Source
    • 14.8.4 Saudi Arabia
      • 14.8.4.1 Segmentation By Component
        • 14.8.4.1.1 Data Platforms and Networks
        • 14.8.4.1.2 Analytics and Technology
      • 14.8.4.2 Segmentation By Technology
        • 14.8.4.2.1 Natural Language Processing (NLP)
        • 14.8.4.2.2 Machine Learning (ML) and Predictive Analytics
        • 14.8.4.2.3 Other Technology
      • 14.8.4.3 Segmentation By End User
        • 14.8.4.3.1 Pharmaceutical and Biotech Companies
        • 14.8.4.3.2 Healthcare Providers and Payers
        • 14.8.4.3.3 Contract Research Organizations (CROs)
        • 14.8.4.3.4 Other End User
      • 14.8.4.4 Segmentation By Data Source
        • 14.8.4.4.1 Electronic Health Records (EHR)
        • 14.8.4.4.2 Claims and Billing Data
        • 14.8.4.4.3 Genomic and Omics Data
        • 14.8.4.4.4 Patient Registries
        • 14.8.4.4.5 Other Data Source
    • 14.8.5 South Africa
      • 14.8.5.1 Segmentation By Component
        • 14.8.5.1.1 Data Platforms and Networks
        • 14.8.5.1.2 Analytics and Technology
      • 14.8.5.2 Segmentation By Technology
        • 14.8.5.2.1 Natural Language Processing (NLP)
        • 14.8.5.2.2 Machine Learning (ML) and Predictive Analytics
        • 14.8.5.2.3 Other Technology
      • 14.8.5.3 Segmentation By End User
        • 14.8.5.3.1 Pharmaceutical and Biotech Companies
        • 14.8.5.3.2 Healthcare Providers and Payers
        • 14.8.5.3.3 Contract Research Organizations (CROs)
        • 14.8.5.3.4 Other End User
      • 14.8.5.4 Segmentation By Data Source
        • 14.8.5.4.1 Electronic Health Records (EHR)
        • 14.8.5.4.2 Claims and Billing Data
        • 14.8.5.4.3 Genomic and Omics Data
        • 14.8.5.4.4 Patient Registries
        • 14.8.5.4.5 Other Data Source
    • 14.8.6 Nigeria
      • 14.8.6.1 Segmentation By Component
        • 14.8.6.1.1 Data Platforms and Networks
        • 14.8.6.1.2 Analytics and Technology
      • 14.8.6.2 Segmentation By Technology
        • 14.8.6.2.1 Natural Language Processing (NLP)
        • 14.8.6.2.2 Machine Learning (ML) and Predictive Analytics
        • 14.8.6.2.3 Other Technology
      • 14.8.6.3 Segmentation By End User
        • 14.8.6.3.1 Pharmaceutical and Biotech Companies
        • 14.8.6.3.2 Healthcare Providers and Payers
        • 14.8.6.3.3 Contract Research Organizations (CROs)
        • 14.8.6.3.4 Other End User
      • 14.8.6.4 Segmentation By Data Source
        • 14.8.6.4.1 Electronic Health Records (EHR)
        • 14.8.6.4.2 Claims and Billing Data
        • 14.8.6.4.3 Genomic and Omics Data
        • 14.8.6.4.4 Patient Registries
        • 14.8.6.4.5 Other Data Source
    • 14.8.7 Rest of LAMEA
      • 14.8.7.1 Segmentation By Component
        • 14.8.7.1.1 Data Platforms and Networks
        • 14.8.7.1.2 Analytics and Technology
      • 14.8.7.2 Segmentation By Technology
        • 14.8.7.2.1 Natural Language Processing (NLP)
        • 14.8.7.2.2 Machine Learning (ML) and Predictive Analytics
        • 14.8.7.2.3 Other Technology
      • 14.8.7.3 Segmentation By End User
        • 14.8.7.3.1 Pharmaceutical and Biotech Companies
        • 14.8.7.3.2 Healthcare Providers and Payers
        • 14.8.7.3.3 Contract Research Organizations (CROs)
        • 14.8.7.3.4 Other End User
      • 14.8.7.4 Segmentation By Data Source
        • 14.8.7.4.1 Electronic Health Records (EHR)
        • 14.8.7.4.2 Claims and Billing Data
        • 14.8.7.4.3 Genomic and Omics Data
        • 14.8.7.4.4 Patient Registries
        • 14.8.7.4.5 Other Data Source

Chapter 15. Company Snapshot

  • 15.1 IQVIA Holdings, Inc.
    • 15.1.1 Business Overview
    • 15.1.2 Key Information
    • 15.1.3 Company Focus
    • 15.1.4 Strategic Insights
    • 15.1.5 Strategy Deployed
    • 15.1.6 Product & Service Portfolio
    • 15.1.7 Capability Overview
    • 15.1.8 Technology & Innovation Focus
    • 15.1.9 Customers / End Users
    • 15.1.10 Competitive Positioning
    • 15.1.11 Key Differentiators
    • 15.1.12 Portfolio Matrix
    • 15.1.13 SWOT Analysis
    • 15.1.14 Future Outlook
  • 15.2 Optum, Inc. (UnitedHealth Group, Inc.)
    • 15.2.1 Business Overview
    • 15.2.2 Key Information
    • 15.2.3 Company Focus
    • 15.2.4 Strategic Insights
    • 15.2.5 Strategy Deployed
    • 15.2.6 Product & Service Portfolio
    • 15.2.7 Capability Overview
    • 15.2.8 Technology & Innovation Focus
    • 15.2.9 Customers / End Users
    • 15.2.10 Competitive Positioning
    • 15.2.11 Key Differentiators
    • 15.2.12 Portfolio Matrix
    • 15.2.13 SWOT Analysis
    • 15.2.14 Future Outlook
  • 15.3 Flatiron Health, Inc.
    • 15.3.1 Business Overview
    • 15.3.2 Key Information
    • 15.3.3 Company Focus
    • 15.3.4 Strategic Insights
    • 15.3.5 Strategy Deployed
    • 15.3.6 Product & Service Portfolio
    • 15.3.7 Capability Overview
    • 15.3.8 Technology & Innovation Focus
    • 15.3.9 Customers / End Users
    • 15.3.10 Competitive Positioning
    • 15.3.11 Key Differentiators
    • 15.3.12 Portfolio Matrix
    • 15.3.13 SWOT Analysis
    • 15.3.14 Future Outlook
  • 15.4 TriNetX, LLC
    • 15.4.1 Business Overview
    • 15.4.2 Key Information
    • 15.4.3 Company Focus
    • 15.4.4 Strategic Insights
    • 15.4.5 Strategy Deployed
    • 15.4.6 Product & Service Portfolio
    • 15.4.7 Capability Overview
    • 15.4.8 Technology & Innovation Focus
    • 15.4.9 Customers / End Users
    • 15.4.10 Competitive Positioning
    • 15.4.11 Key Differentiators
    • 15.4.12 Portfolio Matrix
    • 15.4.13 SWOT Analysis
    • 15.4.14 Future Outlook
  • 15.5 Komodo Health, Inc.
    • 15.5.1 Business Overview
    • 15.5.2 Key Information
    • 15.5.3 Company Focus
    • 15.5.4 Strategic Insights
    • 15.5.5 Strategy Deployed
    • 15.5.6 Product & Service Portfolio
    • 15.5.7 Capability Overview
    • 15.5.8 Technology & Innovation Focus
    • 15.5.9 Customers / End Users
    • 15.5.10 Competitive Positioning
    • 15.5.11 Key Differentiators
    • 15.5.12 Portfolio Matrix
    • 15.5.13 SWOT Analysis
    • 15.5.14 Future Outlook
  • 15.6 Oracle Corporation
    • 15.6.1 Business Overview
    • 15.6.2 Key Information
    • 15.6.3 Company Focus
    • 15.6.4 Strategic Insights
    • 15.6.5 Strategy Deployed
    • 15.6.6 Product & Service Portfolio
    • 15.6.7 Capability Overview
    • 15.6.8 Technology & Innovation Focus
    • 15.6.9 Customers / End Users
    • 15.6.10 Competitive Positioning
    • 15.6.11 Key Differentiators
    • 15.6.12 Portfolio Matrix
    • 15.6.13 SWOT Analysis
    • 15.6.14 Future Outlook
  • 15.7 SAS Institute Inc.
    • 15.7.1 Business Overview
    • 15.7.2 Key Information
    • 15.7.3 Company Focus
    • 15.7.4 Strategic Insights
    • 15.7.5 Strategy Deployed
    • 15.7.6 Product & Service Portfolio
    • 15.7.7 Capability Overview
    • 15.7.8 Technology & Innovation Focus
    • 15.7.9 Customers / End Users
    • 15.7.10 Competitive Positioning
    • 15.7.11 Key Differentiators
    • 15.7.12 Portfolio Matrix
    • 15.7.13 SWOT Analysis
    • 15.7.14 Future Outlook
  • 15.8 Aetion, Inc.
    • 15.8.1 Business Overview
    • 15.8.2 Key Information
    • 15.8.3 Company Focus
    • 15.8.4 Strategic Insights
    • 15.8.5 Strategy Deployed
    • 15.8.6 Product & Service Portfolio
    • 15.8.7 Capability Overview
    • 15.8.8 Technology & Innovation Focus
    • 15.8.9 Customers / End Users
    • 15.8.10 Competitive Positioning
    • 15.8.11 Key Differentiators
    • 15.8.12 Portfolio Matrix
    • 15.8.13 SWOT Analysis
    • 15.8.14 Future Outlook
  • 15.9 ICON plc
    • 15.9.1 Business Overview
    • 15.9.2 Key Information
    • 15.9.3 Company Focus
    • 15.9.4 Strategic Insights
    • 15.9.5 Strategy Deployed
    • 15.9.6 Product & Service Portfolio
    • 15.9.7 Capability Overview
    • 15.9.8 Technology & Innovation Focus
    • 15.9.9 Customers / End Users
    • 15.9.10 Competitive Positioning
    • 15.9.11 Key Differentiators
    • 15.9.12 Portfolio Matrix
    • 15.9.13 SWOT Analysis
    • 15.9.14 Future Outlook
  • 15.10 Syneos Health
    • 15.10.1 Business Overview
    • 15.10.2 Key Information
    • 15.10.3 Company Focus
    • 15.10.4 Strategic Insights
    • 15.10.5 Strategy Deployed
    • 15.10.6 Product & Service Portfolio
    • 15.10.7 Capability Overview
    • 15.10.8 Technology & Innovation Focus
    • 15.10.9 Customers / End Users
    • 15.10.10 Competitive Positioning
    • 15.10.11 Key Differentiators
    • 15.10.12 Portfolio Matrix
    • 15.10.13 SWOT Analysis
    • 15.10.14 Future Outlook

Chapter 16. Winning Imperatives of AI In Evidence Access And Networks Market

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
문의하기